...
首页> 外文期刊>Veterinary and Comparative Oncology >Electrochemotherapy in treatment of canine oral non-tonsillar squamous cell carcinoma. A case series report
【24h】

Electrochemotherapy in treatment of canine oral non-tonsillar squamous cell carcinoma. A case series report

机译:电化学疗法治疗犬口腔非扁桃体鳞状细胞癌。 案例系列报告

获取原文
获取原文并翻译 | 示例
           

摘要

Non-tonsillar squamous cell carcinoma (ntSCC) is a common and locally aggressive oral tumour in dogs. The treatments of choice are currently surgery and radiotherapy. Electrochemotherapy (ECT) is a local ablative anti-tumour technique using electric pulses to enhance the intracellular diffusion of cytotoxic drugs. The aim was to retrospectively evaluate the outcome of patients with oral ntSCC treated with ECT. Twelve dogs with ntSCC were retrospectively enrolled. ECT was combined with IV bleomycin (15 000 UI/m(2)) alone in 11 cases and post-surgery in 1. Parameters considered were: tumour site and size, electroporation parameters, response rate (complete remission [CR], partial remission [PR]), median survival time (MST), recurrence rate (RR), median disease-free interval (DFI) and treatment toxicity (6-point scale). Median tumour size was 1.65 cm (range 0.3-8.0 cm) and the response rate was 90.9% (10/11; 8 CR and 2 PR). Two dogs underwent a second ECT. MST for dogs dead with tumour (n = 2) was 110 days and for dogs dead without tumour (n = 3) was 831 days. Among five surviving dogs, one experienced tumour recurrence and four were in CR. Results from two dogs were analysed separately. Overall RR was 27.3%. DFI and MST for dogs with recurrence were 50 and 115 days, respectively. Treatment toxicity was very low. We noticed that all dogs with tumours smaller than 1-2 cm achieved CR without recurrence suggesting a favourable prognosis when using ECT. ECT for canine ntSCC could be considered a valid treatment option especially for smaller tumours, but a larger caseload would be needed to confirm this statement.
机译:非扁桃体鳞状细胞癌(NTSCC)是狗的常见和局部侵袭性的口腔肿瘤。选择的治疗目前是手术和放射疗法。电化学疗法(ECT)是使用电脉冲的局部烧蚀抗肿瘤技术,以增强细胞毒性药物的细胞内扩散。目的是回顾性地评估口腔NTSCC患者的结果。回顾性地注册了12只狗的NTSCC。在11例中单独使用IV Bleomycin(15 000 uI / m(2)),并且在术后参数考虑为:肿瘤部位和大小,电穿孔参数,反应率(完全缓解[Cr],部分缓解[PR]),中位存活时间(MST),复发率(RR),中位无病区间隔(DFI)和治疗毒性(6分尺寸)。中值肿瘤大小为1.65厘米(范围为0.3-8.0cm),响应率为90.9%(10/11; 8 CR和2 PR)。两只狗经历了第二个等。用肿瘤死亡的狗(n = 2)是110天,对于没有肿瘤的狗(n = 3)为831天。在五只幸存的犬中,一个经历过肿瘤复发和四个在Cr中。两只狗的结果分别分析。总体RR为27.3%。患有复发的DFI和MST分别为50和115天。治疗毒性非常低。我们注意到,所有具有小于1-2厘米的肿瘤的狗都会实现了CR,而不经常出现,表明使用ECT时的良好预后。对于犬NTSCC的ECT可以被认为是一个有效的治疗选项,特别是对于较小的肿瘤,但需要更大的案例来确认这一陈述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号